Revenue segments as reported by the company.

MedSurg and Neurotechnology

Orthopaedics and Spine

Orthopaedics

MedSurg

Neurotechnology and Spine

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research, development and engineering

Selling, general and administrative

Recall charges

Amortization of intangible assets

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Stryker

MAKO was a publicly traded medical device company based in Florida. On September 25, 2013, the Board of Directors of Mako Surgical accepted a deal to be acquired by Stryker for $1.65B. The deal closed in December 2013. The company manufactures and markets surgical robotic arm assistance platforms, most notably the RIO as well as orthopedic implants used by orthopedic surgeons for use in partial knee and total hip arthroplasty. They are known for their intellectual property of devices and have over 300 U.S. and foreign patents and patent applications.

MAKO Surgical Corp

Stryker Corp. is a medical technology company, which engages in the provision of products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery. The Orthopaedics and Spine segment focuses on implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar, and interbody systems used in spinal injury, deformity, and degenerative therapies. The company was founded by Homer H. Stryker in 1941 and is headquartered in Portage, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Stryker (SYK) exceeds Q4 expectations, poised for growth in 2023

Stryker (SYK) delivered exceptional financial results in Q4 2022, surpassing expectations and demonstrating resilience amid challenges. The company is well-positioned for growth with a strong pipeline of products and a focus on margin expansion. Despite ongoing market complexities, Stryker remains optimistic about its future performance.

Stryker reports robust Q1 results and optimistic outlook for 2023

Stryker's strong Q1 performance driven by organic sales growth and increased EPS, with positive outlook for the full year.
Company recognized for workplace excellence, leading in robotics, and expecting growth in medical division.
Challenges include supply chain uncertainties, margin impacts, and market disruptions, but opportunities lie in stakeholder engagement and business expansion.
Overall, Stryker remains focused on innovation, debt reduction, and strategic acquisitions for future growth.

Stryker reports stellar Q2 results, eyes international growth opportunities

Stryker's Q2 performance reflects robust sales growth, margin improvement, and strategic acquisitions driving financial strength.
While facing challenges in the U.S. market and competitive landscapes, Stryker's focus on innovation and international growth presents promising opportunities.
The company's financial resilience, debt reduction strategy, and upcoming product launches position Stryker for sustained success and market expansion.
Overall, Stryker's strong performance, coupled with a focus on innovation and strategic growth initiatives, sets a positive trajectory for future success.

Stryker reports robust Q3 earnings, eyes international growth and M&A

Stryker's Q3 performance reflects strong sales growth and earnings increase, driven by key segments and product lines. Challenges include market competition and potential shifts in procedure trends, while opportunities exist in international expansion and strategic acquisitions.

Stryker exceeds $20B in sales, eyes continued growth and innovation

Stryker's Q4 performance showcased strong sales growth, margin expansion, and successful acquisitions, positioning the company for continued success.
While facing challenges in pricing and potential regulatory impacts, Stryker's focus on innovation and strategic growth initiatives presents promising opportunities.
The company's robust pipeline of innovative products and successful integration efforts highlight its resilience and potential for sustained growth.
With a solid financial foundation and strategic vision, Stryker is well-positioned to capitalize on market opportunities and drive future profitability.

Stryker reports strong Q1 growth, eyes international expansion opportunities

Stryker's Q1 2024 earnings call reflects strong performance, with double-digit organic sales growth and increased guidance for the full year.
The company's focus on innovation, successful acquisitions, and market recognition position it well for future growth and leadership in key segments.
While facing challenges like regulatory delays and market dependencies, Stryker remains optimistic about meeting targets and driving growth through new products and acquisitions.
Opportunities in international expansion, AI solutions, and continued market growth present avenues for sustained success and market leadership for Stryker.

Stryker reports robust Q2 earnings, raises 2024 outlook on acquisitions and margin expansion

Stryker's strong Q2 performance, strategic acquisitions, and focus on margin expansion position the company for continued growth. Despite challenges like foreign exchange rates and market softness in certain segments, Stryker's product strength, innovation pipeline, and international growth opportunities offer a positive outlook. With a commitment to driving margins and expanding its product portfolio, Stryker remains poised for sustained success in the medical technology industry.

Stryker reports robust Q3 performance with strong growth and strategic acquisitions

Stryker's Q3 showcased strong organic sales and EPS growth, driven by MedSurg and Neurotechnology segments.
Strategic acquisitions, record Mako installations, and operational efficiency improvements underpin performance.
Challenges in the ischemic stroke segment and competitor actions pose risks, while pricing trends and margin efficiencies are under scrutiny.
Opportunities lie in M&A expansion, growth in high-demand areas, and sustained market momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

KALAMAZOO, Mich.--(BUSINESS WIRE)--Stryker announced the launch of its Q Guidance System for spine applications.

Stryker Launches Q Guidance System with Spine Guidance Software

Stryker's (SYK) OptaBlate bone tumor ablation system is set to offer a reliable solution for people living with painful metastatic tumors.

Stryker's (SYK) OptaBlate Tumor Ablation System Gets FDA Nod

Dover

Polaris

Income investors sometimes take the route of finding the best income stocks to meet their needs based upon criteria like dividend safety, dividend growth potential or historical dividend streak. These can help investors find great dividend champions that will provide them with years of income.

3 Undervalued Dividend Champions With High Return Potential

Stryker Corporation (NYSE: SYK) is a “mispriced” stock that has potential to offer lucrative returns over the long term, says Heather Brilliant. She's the Chief Executive of Diamon Hill Capital Management.

Diamon Hill CEO names a ‘mispriced' medical technology stock

Stryker's first bone tumor ablation system with patented microinfusion technology offers a reliable solution for people living with painful metastatic tumors PORTAGE, Mich., USA, Sept.

Stryker receives FDA clearance for OptaBlate™ Bone Tumor Ablation System

Stryker stock (NYSE: SYK), a medical devices company, has seen a 15% fall this year, in line with the broader S&P500 index, down 17%.

Should You Buy Stryker Stock Around $225?

KALAMAZOO, Mich.--(BUSINESS WIRE)--Stryker launched its Pulse Intelligent Delivery Platform, which will debut at the 2022 American Orthopaedic Foot & Ankle Society Annual Meeting.

Stryker Launches Pulse Intelligent Delivery Platform at the 2022 American Orthopaedic Foot & Ankle Society Annual Meeting

KALAMAZOO, Mich.--(BUSINESS WIRE)--Stryker has launched the Gamma4 System, strengthening the product's 30-year legacy of continuous innovation and clinical history.

Stryker Launches New Gamma4 Hip Fracture Nailing System

Stryker Corporation ( SYK , Financial) has long been one of my favorite health care names as the company provides some market-leading medical devices.

Why Stryker Remains a Top Health Care Name

Kalamazoo, Michigan, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2022 Wells Fargo Securities Healthcare Conference on Thursday, September 8, 2022.

Stryker to participate in the 2022 Wells Fargo Securities Healthcare Conference

Stryker's medical devices reach more than 100 million patients each year.

Why This Dividend Stock Is a Buy

Stryker is a diversified medical technology company with strong sales growth, profitability, and a long history of dividend growth. It's well positioned to invest in strategic growth areas and benefits from favorable demographic tailwinds.

Stryker Is A Moat-Worthy Buy, Here's Why

Kalamazoo Michigan, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.695 per share payable October 31, 2022 to shareholders of record at the close of business on September 30, 2022, representing an increase of 10.3% versus the prior year and unchanged from the previous quarter.

Stryker declares a $0.695 per share quarterly dividend

Stryker's (SYK) second-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurt sales growth.

Stryker's (SYK) Q2 Earnings and Revenues Miss Estimates

Stryker Corporation (NYSE:SYK ) Q2 2022 Earnings Conference Call July 26, 2022 4:30 PM ET Company Participants Kevin Lobo - Chair and Chief Executive Officer Glenn Boehnlein - Chief Financial Officer Jason Beach - Vice President, Investor Relations Conference Call Participants Robbie Marcus - JPMorgan Lawrence Biegelsen - Wells Fargo Vijay Kumar - Evercore Pito Chickering - Deutsche Bank Matthew O'Brien - Piper Sandler Joanne Wuensch - Citi Joshua Jennings - Cowen Kyle Rose - Canaccord Chris Pasquale - Nephron Research Steve Lichtman - with Oppenheimer Travis Steed - Bank of America Drew Ranieri - Morgan Stanley Michael Matson - Needham & Company Jeff Johnson - Baird Shagun Singh - RBC Ryan Zimmerman - BTIG Operator Welcome to the Second Quarter 2022 Stryker Earnings Call. My name is Hannah and I will be your operator for today's call.

Stryker Corporation (SYK) CEO Kevin Lobo on Q2 2022 Results - Earnings Call Transcript

Stryker (SYK) delivered earnings and revenue surprises of -0.88% and 0.78%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Stryker (SYK) Lags Q2 Earnings and Revenue Estimates

Stryker stock fell late Tuesday after the company trimmed its full-year earnings outlook following its second-quarter miss. The post Stryker Stock Wipes Out As Strong Dollar Squeezes Outlook After Quarterly Miss appeared first on Investor's Business Daily.

Stryker Stock Wipes Out As Strong Dollar Squeezes Outlook After Quarterly Miss

Kalamazoo, Michigan, July 26, 2022 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the second quarter of 2022:

Stryker reports second quarter 2022 operating results

Johnson & Johnson

Intuitive Surgical

Zimmer Biomet Hlds

While Johnson & Johnson's ( JNJ , Financial) Medtech sales were lower in the second quarter, revenue from hips and knee replacements was on target or above, a development that could spill over into segment competitors Stryker Corp. ( SYK , Financial) and Zimmer Bioment Holdings Inc. ( ZBH , Financial), as well as robotic surgery leader Intuitive Surgical Inc. ( ISRG , Financial), analysts said in a Fierce Pharma article.

J&J Medtech Outlook Boosts Shares of Stryker, Biomet and Intuitive

The bone cement market size was estimated at $716.9 million in 2021 The bone cement market size was estimated at $716.9 million in 2021

Stryker Corp and Zimmer Biomet Holdings Inc Among Leading Companies in the Bone Cement Market | Globaldata Plc

Kalamazoo, Michigan, June 30, 2022 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will host a conference call on Tuesday, July 26, 2022 at 4:30 p.m., Eastern Time, to discuss the Company's operating results for the quarter ended June 30, 2022 and provide an operational update. Final operating results for the quarter ended June 30, 2022 will be released at 4:05 p.m. that day.

Stryker to host conference call on July 26, 2022

Stryker's (SYK) participation at the WIC in China marks a milestone for the company as it can bring more Advanced Digital Healthcare solutions to the China market.

Stryker (SYK) to Boost Presence in China Via Digital Healthcare

KALAMAZOO, Mich.--(BUSINESS WIRE)-- #rebuildinglivestogether--Stryker (NYSE:SYK), one of the world's leading medical technology companies, today launched an experiential campaign to inspire consumers to explore new treatment options for bunions and increase awareness of the benefits of bunion surgery. The interactive campaign consists of visually creative chalk designs in four major metropolitan cities – New York City, Los Angeles, Chicago and Miami – prompting passersby to learn more. From June 27 through Sept. 29, the

Stryker Launches “Free Your Feet” Campaign to Raise Awareness About New Bunion Treatments

SHANGHAI , June 24, 2022 /PRNewswire/ -- Stryker (NYSE:SYK), a leading medical technologies company, attended the 6th World Intelligence Congress (WIC) in China, showcasing how its Advanced Digital Healthcare solutions brings clinical, operational and financial values for the healthcare market. This is the first time for Stryker to participate in WIC as a strategic partner in healthcare industry, marking a significant milestone for Stryker as it brings more Advanced Digital Healthcare solutions to the China market.

Stryker's debut at World Intelligence Congress: Bringing Stryker's Advanced Digital Healthcare to China

Alnylam Pharmaceuticals

Baxter

Biogen

Boston Scientific

Cardinal Health

Gilead Sciences

Karuna Therapeutics Inc

Medtronic

Mirati Therapeutics

Natera

Roche Holding AG

Vertex Pharmaceuticals

SPDR S&P Biotech ETF

If you have the discipline to think long-term as an investor, this is the time to take advantage of the steep discounts on great biotechnology companies.

News for Stryker Stock (SYK)